Company news
Biovaxys Technology Corp (CSE:BIOV) news
Biovaxys Technology Corp news releases on 6ix. Latest, Sep 8, 2026: BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth…
Press releases & updates
BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
September 8, 2026
BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer
May 1, 2026
BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2026
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
March 17, 2026
BioVaxys Announces Application for Management Cease Trade Order
March 3, 2026
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
January 29, 2026
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
January 20, 2026
BioVaxys 1Q2026 R&D and Collaborative Activity
January 15, 2026
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
January 8, 2026
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
December 17, 2025
BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
December 15, 2025
BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
November 19, 2025
BioVaxys Announces Extension of Life Offering Closing Date
November 11, 2025
BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
October 30, 2025
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
October 28, 2025
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS
October 20, 2025
BioVaxys Technology : Annual MD&A
October 18, 2025
BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
October 14, 2025
BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS
October 8, 2025
BIOVAXYS ANNOUNCES LIFE OFFERING
October 7, 2025
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
September 29, 2025
BIOVAXYS ANNOUNCES CLOSING OF UNSECURED CONVERTIBLE DEBENTURE OFFERING
September 16, 2025
BIOVAXYS ANNOUNCES SHARE CONSOLIDATION
September 5, 2025
BIOVAXYS ANNOUNCES UNSECURED CONVERTIBLE DEBENTURE OFFERING AND CANCELLATION OF BROKERED LIFE OFFERING
August 27, 2025
BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE
July 15, 2025
BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE PLACEMENT OFFERING
July 7, 2025
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
June 20, 2025
BioVaxys Issues Corporate Update
June 3, 2025
BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT OFFERING FOR GROSS PROCEEDS OF UP TO $3,000,000
May 30, 2025
BioVaxys and Sona Nanotech Enter Research Collaboration
May 7, 2025
BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture
April 22, 2025
BioVaxys Technology Corp. Announces Revocation of Management Cease Trade Order and Closing of Debt Settlement Transaction
April 10, 2025
BioVaxys Technology Corp. Granted Management Cease Trade Order
March 3, 2025
BioVaxys Announces Debt Settlement Agreement, Extension of Private Placement Closing Date and Closing of The Fourth and Final Tranche of Private Placement
February 18, 2025
BioVaxys Announces Sale of TAET Software Co
June 14, 2023
BioVaxys details shareholder value with retention of Maxim to achieve US stock exchange listing
April 19, 2023
Headline
April 19, 2023
BioVaxys acquires TAETSoftware to utilize Trial Adverse Events Tracker platform
March 17, 2023